Treatment of disease with n-acetyl kynurenine

a technology of n-acetyl kynurenine and n-acetyl kynurenine, which is applied in the direction of organic active ingredients, drug compositions, immunological disorders, etc., can solve the problems that the presence of n-acetyl kynurenine in low molecular weight fractions of human serum albumin has not been previously recognized, and no biological activity of n-acetyl kynurenine has

Inactive Publication Date: 2019-07-04
AMPIO PHARMA
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a method for treating various T-cell mediated diseases, degenerative joint diseases, and diseases mediated by platelet activating factor using a pharmaceutical composition containing N-acetyl-kynurenine or a salt thereof. The treatment involves administering the pharmaceutical composition to an animal in need thereof. The invention has been found to be effective in treating these diseases in animals, including humans, and can be administered through various routes such as injection, topical, local, transdermal, inhalation, and eye drops. The pharmaceutical composition can also be combined with other active agents such as analgesics, anti-inflammatory drugs, and combinations thereof to provide enhanced treatment efficacy. The technical effect of the invention is to provide a novel pharmaceutical composition for the treatment of various T-cell mediated diseases, degenerative joint diseases, and diseases mediated by platelet activating factor.

Problems solved by technology

However, no biological activity of N-acetyl-kynurenine has been reported, with the exception as a UV filter in the lenses of the ground squirrel (Hains et al.).
Further, the presence of this compound in low molecular weight fractions of human serum albumin has not been previously recognized.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of disease with n-acetyl kynurenine
  • Treatment of disease with n-acetyl kynurenine
  • Treatment of disease with n-acetyl kynurenine

Examples

Experimental program
Comparison scheme
Effect test

example

[0072]This example characterizes LMWF5A using liquid chromatography tandem-mass spectrometry (LCMS-MS) and other techniques to identify non-enzymatic breakdown products of N-acetyl tryptophan (NAT). Thermal forced degradation conditions were also applied in order to increase the amount of NAT breakdown products to improve detection and identification.

[0073]The excipient NAT is added at a concentration of 4 mM to 5% commercial solutions of human serum albumin (HSA) for the purpose of stabilizing the protein during the pasteurization process. It has been postulated that NAT provides a protective effect on the free sulfhydryl group (Cys-34) of HSA thereby diminishing protein oxidation. In the study below, the low molecular weight fraction of 5% HSA (LMWF5A) was shown to contain breakdown products of NAT. This is the first study to specifically describe the presence of N-acetyl kynurenine in a solution derived from commercially available HSA. In summary, breakdown products of NAT were d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Compositionaaaaaaaaaa
Login to view more

Abstract

The invention provides a method, composition and kit for treating T-cell mediated diseases, degenerative joint diseases or diseases mediated by platelet activating factor (PAF) comprising administering to an animal in need thereof, an effective amount a pharmaceutical composition containing N-acetyl-kynurenine (NAK) or pharmaceutically acceptable salts thereof as the active ingredient.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 62 / 381,824, filed Aug. 31, 2016. The entire disclosure of U.S. Provisional Patent Application No. 62 / 381,824 is incorporated herein by referenceFIELD OF THE INVENTION[0002]The invention relates to a method, composition and kit for treating T-cell mediated diseases, degenerative joint diseases or diseases mediated by platelet activating factor (PAF) by administration of a pharmaceutical composition containing N-acetyl-kynurenine (NAK) as the active ingredient and related pharmaceutical compositions.BACKGROUND[0003]The low molecular weight fraction of 5% human serum albumin (LMWF5A) is a biological that has anti-inflammatory and pain relief properties in the treatment of various chronic conditions such as osteoarthritis. In addition to marked improvements in clinical trials, LMWF5A increases biomarkers of resolution of inflamm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/198A61K45/06A61P19/02A61P29/00A61P37/06
CPCA61K31/198A61K45/06A61P19/02A61P29/00A61P37/06A61K9/0019
Inventor BAR-OR, DAVIDRAEL, LEONARD T.BAR-OR, RAPHAEL
Owner AMPIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap